1-7 of 7
Timothy Price
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials

Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, Dongsheng Tu, Stephanie Y. Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O'Callaghan, Jonathan M. Loree
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1121–1130.
https://doi.org/10.1158/1078-0432.CCR-23-3275
Published: 15 March 2024
View article titled, Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Open the PDF for Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

Jonathan M. Loree, Anthony Dowers, Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O'Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 52–59.
https://doi.org/10.1158/1078-0432.CCR-20-2710
Published: 04 January 2021
View article titled, Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Open the PDF for Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial in another window
Includes: Supplementary data
Journal Articles

Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy

Vignesh Narasimhan, Josephine A. Wright, Michael Churchill, Tongtong Wang, Rachele Rosati, Tamsin R.M. Lannagan, Laura Vrbanac, Anne B. Richardson, Hiroki Kobayashi, Timothy Price, Gayle X.Y. Tye, Julie Marker, Peter J. Hewett, Michael P. Flood, Shalini Pereira, G. Adam Whitney, Michael Michael, Jeanne Tie, Siddhartha Mukherjee, Carla Grandori, Alexander G. Heriot, Daniel L. Worthley, Robert G. Ramsay, Susan L. Woods
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3662–3670.
https://doi.org/10.1158/1078-0432.CCR-20-0073
Published: 15 July 2020
View article titled, Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Open the PDF for Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy in another window
Includes: Supplementary data
Journal Articles

Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study

Marc Peeters, Timothy Price, Michael Boedigheimer, Tae Won Kim, Paul Ruff, Peter Gibbs, Anne Thomas, Gaston Demonty, Kristina Hool, Agnes Ang
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1216–1225.
https://doi.org/10.1158/1078-0432.CCR-18-2072
Published: 15 February 2019
View article titled, Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Open the PDF for Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study in another window
Includes: Supplementary data
Journal Articles

Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer

Tae Won Kim, Marc Peeters, Anne Thomas, Peter Gibbs, Kristina Hool, Jianqi Zhang, Agnes Lee Ang, Bruce Allen Bach, Timothy Price
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (22): 5602–5609.
https://doi.org/10.1158/1078-0432.CCR-17-3377
Published: 15 November 2018
View article titled, Impact of Emergent Circulating Tumor DNA <em>RAS</em> Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer
Open the PDF for Impact of Emergent Circulating Tumor DNA <em>RAS</em> Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer

Amanda Townsend, Niall Tebbutt, Christos Karapetis, Pamela Cooper, Nimit Singhal, Susan Yeend, Louise Pirc, Rohit Joshi, Jennifer Hardingham, Timothy Price
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (16): 3838–3844.
https://doi.org/10.1158/1078-0432.CCR-17-3590
Published: 14 August 2018
View article titled, Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <em>KRAS</em> Wild-Type Metastatic Colorectal Cancer
Open the PDF for Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <em>KRAS</em> Wild-Type Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

Simon J. Harrison, Paul Mainwaring, Timothy Price, Michael J. Millward, Peeter Padrik, Craig R. Underhill, Paul K. Cannell, Steven D. Reich, Mohit Trikha, Andrew Spencer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (18): 4559–4566.
https://doi.org/10.1158/1078-0432.CCR-15-2616
Published: 15 September 2016
View article titled, Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results
Open the PDF for Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results in another window